Mild to moderate asthmatics Respiratory Asthma
Conditions
Interventions
This study involves a number of tests which are designed to understand the mechanisms of cough in asthma and include: exhaled nitric oxide, breath test, spirometry, 24 hr cough monitoring, skin allerg
Sponsors
University Hospital of South Manchester NHS Foundation Trust (UK)
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Aged 18 years or over 2. Person with a primary or secondary care doctor diagnosis of asthma 3. The subject is treated with: 3.1. Short-acting beta 2 agonist 3.2. AND/OR inhaled corticosteroid (=500 mcg fluticasone propionate daily or equivalent) 3.3. AND/OR a long-acting beta 2 agonist 3.4. AND/OR a leukotriene receptor antagonist 4. Controlled or has partial asthma control according to the GINA classification
Exclusion criteria
Exclusion criteria: 1. Symptoms of upper respiratory tract infection (URTI) in the last 1 month which have not resolved. 2. Lower respiratory tract infection or pneumonia in the last 6 weeks. 3. Current smoker or ex-smoker with =10 pack-year smoking history, abstinence of 6 months or lesser 4. Asthma exacerbation in the previous month requiring an increase or starting of an ICS or OCS 5. Asthma medication which includes theophylline or anti-cholinergic drugs. 6. Subject has changed asthma medication within the past 4 weeks prior to screening 7. A previous asthma exacerbation requiring Intensive Care Unit (ICU) admission. 8. Significant other primary pulmonary disorders, in particular; pulmonary embolism, pulmonary hypertension, interstitial lung disease, lung cancer, cystic fibrosis, emphysema or bronchiectasis. 9. Pregnancy or breast-feeding 10. Use of ACE inhibitors 11. Any centrally acting medication which in the view of the investigator could alter the sensitivity of the cough reflex 12. History of psychiatric illness, drug or alcohol abuse which may interfere in the participation of the trial.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The influence of allergic inflammation on capsaicin dose response curves (ED50/Emax)* in mild to moderate asthmatics. * Emax is the maximum number of coughs provoked and ED50 is the capsaicin dose provoking half the Emax. Primary and secondary outcomes will be measured at baseline only. | — |
Secondary
| Measure | Time frame |
|---|---|
| The influence of airway hyper-responsiveness (PD20 Methacholine), and serum/plasma neurotrophin levels on ED50 and Emax will also be explored and their relationships with 24 hr cough frequency and Leicester cough questionnaire (LCQ) and asthma control (ACQ). | — |
Countries
United Kingdom
Outcome results
None listed